Navigation Links
Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
Date:9/18/2007

SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will participate in the UBS Global Life Sciences Conference.

UBS Global Life Sciences Conference

Grand Hyatt New York

Thursday, September 27, 2007

9:00 a.m. ET

The presentation will be audio webcast live and available for replay from Dendreon's website, http://www.dendreon.com.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... 2017   Valentin A. Pavlov, PhD , associate ... and CEO of The Feinstein Institute for Medical ... how the nervous system regulates the immune system, which ... medicine devices to treat disease and injury. The ... The paper examines various studies which further ...
(Date:1/13/2017)... 2017 Research and Markets has announced the ... Global Forecast to 2021" report to their offering. ... The biosimilars market is ... Billion in 2016, at a CAGR of 26.3%. ... manufacturing type, and application. Factors such as rising incidence of various ...
(Date:1/12/2017)... ... January 12, 2017 , ... MEXICO’S FIRST ... Inc., announces the successful outcome of the first lumbar fusion procedure in ... Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical Technologies to ...
(Date:1/12/2017)... , January 12, 2017 The ... world,s biggest facility for producing mycorrhizae. The Centre for ... tapping potential of mycorrhizae and developed a technology that ... ... The TERI facility has a ...
Breaking Biology Technology:
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
Breaking Biology News(10 mins):